Raymond James rates HCA Healthcare stock Market Perform

Published on 10/05/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 20.23 billion, up 8.70 percent. HCA Healthcare stock costs EUR 380.55 on October 5, 2026 versus EUR 379.15.

Isometrische 3D-Illustration der Krankenhaus-Wertschöpfungskette: Aufnahme, Diagnose, OP, Pflege, Apotheke — HCA Healthcare US40412C1018 isometrisches Diagramm der Wertschöpfungskette vom Patienten über Diagnose bis zur Apotheke, Illustration mit AI erstellt.

HCA Healthcare (ISIN US40412C1018) received a Market Perform rating from Raymond James on September 28, 2026, as the analyst cited industry headwinds. The assessment puts current attention on payer trends and the hospital operator's second-half execution.

Market Perform meets mixed execution

According to Investing.com on September 28, 2026, Raymond James pointed to Medicaid work requirements, spending caps and unfavorable exchange trends. The firm also said the second half of 2026 requires material acceleration in the company's underlying trajectory.

The caution follows a strong second quarter. HCA Healthcare reported adjusted earnings of USD 7.59 per share on revenue of USD 20.23 billion, while forecasts cited by Investing.com were USD 7.40 and USD 19.38 billion, respectively.

Revenue growth remains measurable

Revenue in the second quarter of 2026 increased 8.70 percent year over year, according to Investing.com. The comparison is important because the company exceeded cited revenue expectations by USD 0.85 billion, although the same report said HCA adjusted its full-year profit guidance after changes in payer mix.

MarketBeat reported USD 20.23 billion in quarterly revenue and adjusted earnings of USD 7.59 per share, with revenue growth of 8.70 percent compared with the prior-year quarter. The figures show why the debate has shifted from demand alone to the durability of margins and reimbursement conditions.

October earnings date is set

HCA Healthcare has scheduled its third-quarter 2026 earnings call for October 27, 2026, at 10:00 a.m. Eastern, according to the company's HCA Healthcare investor release dated September 30, 2026. That report will give investors a fresh test of the exchange headwinds and the acceleration described by Raymond James.

HCA Healthcare stock and the next test

HCA Healthcare was trading at EUR 380.55 at Lang & Schwarz on October 5, 2026 at 1:43 p.m. CEST, plus 0.37 percent versus the Lang & Schwarz prior close of EUR 379.15 on October 2, 2026. The next major company date is October 27, 2026, when the third-quarter update is due.

The further course of trading is shown by the continuously updated real-time quote of HCA Healthcare stock.